stockrowMaravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
Follow MRVI
Alert me
Maravai LifeSciences Holdings, Inc. (MRVI) Revenue
Maravai LifeSciences Holdings, Inc.'s revenue for fiscal 2025 was $185.7M, down 28.3% from $259.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $213.0M. Over the past ten years it has ranged from $123.8M (fiscal 2018) to $883.0M (fiscal 2022); the current reading is higher than 38% of that period. Revenue has fallen for 3 consecutive fiscal years. Maravai LifeSciences Holdings, Inc. ranks 69th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $185.7M | (28.34%) |
| FY2024 | $259.2M | (10.30%) |
| FY2023 | $288.9M | (67.28%) |
| FY2022 | $883.0M | 10.48% |
| FY2021 | $799.2M | 181.33% |
| FY2020 | $284.1M | 98.48% |
| FY2019 | $143.1M | 15.59% |
| FY2018 | $123.8M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $45.9M | (10.87%) |
| Jun 2026 | $51.4M | (21.86%) |
| Mar 2026 | $65.8M | 32.03% |
| Dec 2025 | $49.9M | 19.78% |
| 24 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| SRPT Sarepta Therapeutics, Inc. compare | $2.0B |
| HRMY Harmony Biosciences Holdings, Inc. compare | $989.4M |
| VIR Vir Biotechnology, Inc. compare | $302.8M |
| MRVI Maravai LifeSciences Holdings, Inc. | $213.0M |
| MESO Mesoblast Limited compare | $7.5M |
| TRVI Trevi Therapeutics, Inc. compare | — |
| MAZE Maze Therapeutics, Inc. compare | — |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item